Project Grant K99HL177315
Award Date 9/25/25
Completion Date 7/31/27
Dollars Obligated $137K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
- This federal Project Grant award of $552,318 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of carbonic anhydrase as a cardioprotective target for mitigating the cardiotoxic effects of anthracycline chemotherapy drugs like doxorubicin. The research leverages human-induced pluripotent stem cell-derived cardiomyocytes to model anthracycline-induced cardiotoxicity and uses CRISPR interference/activation...
- This Project Grant award of $248,999 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Washington University will leverage patient-specific induced pluripotent stem cell (iPSC)-derived cardiac pericytes and endothelial cells to elucidate the molecular and cellular basis of tyrosine kinase inhibitor-induced vascular toxicity (TKI-VT) and discover personalized therapies. The key objectives are to: Characterize sunitinib-induced cytotoxicity...
- The federal Project Grant award of $701,890.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the molecular mechanisms by which the cancer drug sunitinib induces vascular dysfunction. The University of Illinois in Chicago is conducting this research, which aims to better understand sunitinib's effects on the endothelial cells that line blood vessels, in order to mitigate the risk of cardiovascular toxicity...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
- This $645,460 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to gain mechanistic insights and develop predictive tools to address nilotinib-induced artery disease. The 5-year study will recruit 100 nilotinib-treated patients, 50 with and 50 without artery disease, to generate human induced pluripotent stem cells (hiPSCs) for whole genome sequencing and differentiation into endothelial cells. This will help elucidate...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $697,952 to the Beckman Research Institute of the City of Hope to investigate the molecular mechanisms behind cardiotoxicity induced by the tyrosine kinase inhibitor (TKI) drug osimertinib. The key objectives are to: 1) establish a novel mouse model for osimertinib-induced cardiac dysfunction, 2) use single-nucleus RNA sequencing to identify downregulation of...
- This federal Project Grant award of $680,583.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover genetic modifiers and novel therapies for anthracycline-induced cardiotoxicity. The study aims to use zebrafish models to test candidate genes identified from human genome-wide association studies, as well as explore the role of aging-associated epicardial remodeling in cardiotoxicity. Key areas of focus include...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $694,754 to The Washington University to investigate the connections between genotype, molecular/cellular dysfunction, and small molecule treatments for key troponin cardiomyopathy mutations. The 5-year project aims to build a mechanistic understanding of how specific genetic mutations impact contractile function at the molecular, cellular, and tissue levels...
- This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...
- This federal Project Grant award for $802,301, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Weill Medical College of Cornell University to investigate the mechanisms that control the bone marrow "niche" environment and its role in expanding mutated blood stem cells that increase the risk of cardiovascular disease and cancer. The research aims to identify signaling pathways that can be targeted to prevent...